Berlex Ultravist imaging agent will be launched in July; approved May 10, two years after advisory committee.
BERLEX ULTRAVIST CONTRAST AGENT WILL BE AVAILABLE IN JULY, the company announced May 12. The iodinated, non-ionic contrast agent iopromide for x-ray imaging and computed tomography scanning (NDA 20-220) was approved by FDA on May 10, almost two years after FDA's Medical Imaging Drugs Advisory Committee unanimously recommended approval for eight indications ("The Pink Sheet" May 31, 1993, T&G-2).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth